Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer.
about
Bicyclic triterpenoid Iripallidal induces apoptosis and inhibits Akt/mTOR pathway in glioma cellsTubulin-interactive natural products as anticancer agentsFirst-line therapy with gemcitabine and paclitaxel in locally, recurrent or metastatic breast cancer: a phase II study.Paclitaxel targets VEGF-mediated angiogenesis in ovarian cancer treatmentA phase II study of sequential 5-fluorouracil, epirubicin and cyclophosphamide (FEC) and paclitaxel in advanced breast cancer (Protocol PV BC 97/01)High-dose paclitaxel in combination with doxorubicin, cyclophosphamide and peripheral blood progenitor cell rescue in patients with high-risk primary and responding metastatic breast carcinoma: toxicity profile, relationship to paclitaxel pharmacokiPhenethyl isothiocyanate and paclitaxel synergistically enhanced apoptosis and alpha-tubulin hyperacetylation in breast cancer cellsSynergistic effect of paclitaxel and epigenetic agent phenethyl isothiocyanate on growth inhibition, cell cycle arrest and apoptosis in breast cancer cellsRescue of paclitaxel sensitivity by repression of Prohibitin1 in drug-resistant cancer cellsSynthesis and preliminary biological evaluation of high-drug-load paclitaxel-antibody conjugates for tumor-targeted chemotherapyPaclitaxel combined with inhibitors of glucose and hydroperoxide metabolism enhances breast cancer cell killing via H2O2-mediated oxidative stress.Biomechanics and biophysics of cancer cells.Systems biology of cancer: a challenging expedition for clinical and quantitative biologistsSynergistic interactions between aminoflavone, paclitaxel and camptothecin in human breast cancer cellsCisplatin in cancer therapy: molecular mechanisms of actionQuantitative optical imaging of primary tumor organoid metabolism predicts drug response in breast cancer.Taxol inhibits neointimal smooth muscle cell accumulation after angioplasty in the ratComparison of cantharidin toxicity in breast cancer cells to two common chemotherapeuticsProfound and persistent painful paclitaxel peripheral neuropathy in a premenopausal patient.Rationalization of paclitaxel insensitivity of yeast β-tubulin and human βIII-tubulin isotype using principal component analysis.Selective activation of cannabinoid CB2 receptors suppresses neuropathic nociception induced by treatment with the chemotherapeutic agent paclitaxel in ratsNeurosteroid 3α-androstanediol efficiently counteracts paclitaxel-induced peripheral neuropathy and painful symptomsRecent advances in the systemic therapy of breast cancer.Abieslactone induces cell cycle arrest and apoptosis in human hepatocellular carcinomas through the mitochondrial pathway and the generation of reactive oxygen speciesClinical trials in the era of personalized oncology.Paclitaxel impairs adipose stem cell proliferation and differentiation.Vascular endothelial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancerRegulation of microtubule dynamics by DIAPH3 influences amoeboid tumor cell mechanics and sensitivity to taxanesCytotoxic studies of paclitaxel (Taxol) in human tumour cell lines.The shape of things to come: structural and synthetic studies of taxol and related compoundspH-responsive high-density lipoprotein-like nanoparticles to release paclitaxel at acidic pH in cancer chemotherapy.Phase II multi-institutional prospective randomised trial comparing S-1+paclitaxel with S-1+cisplatin in patients with unresectable and/or recurrent advanced gastric cancer.Pathologic complete response rates in triple-negative, HER2-positive, and hormone receptor-positive breast cancers after anthracycline-free neoadjuvant chemotherapy with carboplatin and paclitaxel with or without trastuzumab.A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent breast cancer.Schedule-dependent interaction between paclitaxel and 5-fluorouracil in human carcinoma cell lines in vitro.Effective treatment of advanced breast cancer with vinorelbine, mitomycin C plus human granulocyte colony-stimulating factor.Designing Paclitaxel drug delivery systems aimed at improved patient outcomes: current status and challenges.Enhanced combination therapy effect on paclitaxel-resistant carcinoma by chloroquine co-delivery via liposomesWeekly pegylated liposomal doxorubicin and paclitaxel in patients with metastatic breast carcinoma: A phase II study.Dose-escalation phase I study in metastatic breast cancer patients with combination of paclitaxel and tegafur·uracil
P2860
Q21261315-73BEFB31-B3AD-4ABF-A550-C4E78870C5A6Q24650163-B4CABFC6-D2AC-4C96-966D-96B0E751AC89Q24812405-9E7EE4D1-EC42-4CFE-AEEA-30495E1C08C0Q28073057-A6CFFE20-FDD4-4E7D-8B39-70308A65452DQ28344321-BC940E7C-0751-40CC-AD52-0CA85F99036AQ28366611-81F05D38-888F-46B4-988C-FEA321576C71Q28396209-D17D0040-99AA-42CB-AFC3-1584EC6B5059Q28397373-8F33FEBE-A143-4EA5-82CF-526FB8658A4DQ33664289-8AA8C5CE-5BE6-48D3-AFFD-68845A55DF77Q33737986-0A349D31-4EC9-4E79-93E4-CA72897EF88FQ33746588-29D3B6F1-2154-4237-A069-E1E9DBEFDC86Q34048694-98DC0333-BAAE-4C9D-BACE-6CF055B73AA4Q34064296-98DF112D-EF7F-403D-873B-6C0ADB2B8391Q34096921-2228C288-3A7E-44C7-B5A8-FB7FCE74FDBAQ34098163-5826457F-4B99-47F4-85C9-172B60DB2E71Q34205196-A3ECD5CB-BE1F-413D-AA0B-DAA1D191CB2AQ34211840-3D58EDA5-6500-4303-B2E4-2617D2FEABFDQ34267632-B353900E-17CE-4623-91D5-09E1DB5B9288Q34303792-D6E17DC5-A5D4-4367-9D5B-BCA16DEF8366Q34360044-7FFFC1EC-FB2E-4EB4-8B6D-C51B35ABDAD0Q34802605-631312EF-DFE7-4668-920D-8A2F58310427Q35049356-5FDD2D35-BC53-4E82-9E5F-A8FAFC7EE479Q35052282-C048006E-7A81-46C9-8F8F-D5EA89D31A10Q35515831-C2C56B75-D5B2-439E-A723-8EE9CD503C43Q35555963-E0677105-14C4-4569-8819-880E59DC7239Q35642332-82D135BB-2193-4D4A-9B90-C0DFD33EDC99Q35747792-45AE5F25-618E-4BF5-AA78-50E64FF9C8D3Q35856517-4C6FC58D-A87B-49C3-9494-CEE961967F77Q35977537-A39E6834-C4AD-4469-901A-6ACBEFC74FD4Q35996314-C6C3464D-0A25-483F-A842-2C34393A801CQ36058740-A256DF23-07CA-4766-BD2A-957B6BA4017DQ36075265-7EBFB667-BAB9-4094-BEA8-CD3E31CE77C3Q36132952-C484DA3A-6E30-4E29-9EEC-47471310D337Q36134486-475E5808-A2B6-4501-8D66-1960BB0DF646Q36136024-7E67EF5D-8E46-4CB4-82A9-946217CE6A29Q36136477-0F824EEB-C078-424D-A1C1-767E2CAEF8F8Q36183605-E3F8200F-68BB-4228-BDD0-B35DD2B48B0CQ36212944-90E2AEF2-4CD3-4113-B5EA-9447AAD01906Q36216861-42BB3B9E-4B47-474B-801A-AC93467944E1Q36217005-3C657618-2471-4DB0-A9FA-A3834E2C3AC5
P2860
Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer.
description
1991 nî lūn-bûn
@nan
1991 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1991 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
name
Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer.
@ast
Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer.
@en
type
label
Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer.
@ast
Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer.
@en
prefLabel
Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer.
@ast
Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer.
@en
P2093
P356
P1476
Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer.
@en
P2093
Hortobagyi GN
Theriault RL
Walters RS
P304
P356
10.1093/JNCI/83.24.1797
P407
P577
1991-12-01T00:00:00Z